Technology | Quality Assurance (QA) | July 10, 2019

New SciMoCa Monte Carlo patient QA enables fast and efficient quality assurance accuracy for Varian Halcyon in addition to all other major radiation therapy systems

IBA Launches Monte Carlo Patient QA for Varian Halcyon at AAPM 2019

July 10, 2019 — IBA announced the launch of the latest functionality of the SciMoCa Monte Carlo Patient QA solution at the 61st annual American Association of Physicists in Medicine (AAPM) annual meeting, July 14-18 in San Antonio, Texas. The new release of SciMoCa provides what IBA calls the first and only worldwide commercial Monte Carlo Patient QA for the Varian Halcyon System.

Healthcare professionals can now verify all Halcyon treatment plans independently, accurately, and with an automated and efficient workflow. The fast Monte Carlo dose calculation enables highly accurate results even for the most challenging cases like non-coplanar stereotactic body radiation therapy (SBRT), and in particular for indications with tissue inhomogeneity like lung and head & neck treatments.

Monte Carlo is the gold standard for dose calculation accuracy in treatment planning. With SciMoCa, the accuracy of Monte Carlo is now available for independent secondary dose calculation and patient QA (quality assurance) as well, allowing users to verify the most advanced treatment plans with an equally robust and fast QA solution. SciMoCa is used clinically for all standard linear accelerator (linac) types, for the Accuray CyberKnife and TomoTherapy/Radixact, and is now also compatible with Varian Halcyon.

The high-quality beam models for SciMoCa are created linac-specific for customers applying dedicated processes, expert tools and experience. This process allows an independent verification of the commissioning data and the TPS model, providing an additional level of peace of mind about the accuracy of the machine and TPS commissioning. This is particularly valuable for pre-commissioned treatment machines like Halcyon.

The SciMoCa software is manufactured by Radialogica LLC and globally distributed by IBA Dosimetry.

For more information: www.iba-dosimetry.com

Related Content

News | Lung Imaging

August 10, 2022 — Mount Sinai is leading a team of lung cancer researchers that has been awarded a three-year, $500,000 ...

Time August 10, 2022
arrow
News | Prostate Cancer

August 9, 2022 — Bot Image, an Omaha-based MRI medical device company has developed an AI-driven medical device CAD ...

Time August 09, 2022
arrow
News | Breast Imaging

August 8, 2022 — The U.S. Food and Drug Administration approved Enhertu (fam-trastuzumab-deruxtecan-nxki), an IV ...

Time August 08, 2022
arrow
News | Lung Imaging

August 8, 2022 — Representatives from the Diagnostics Working Group of the IASLC Early Detection and Screening Committee ...

Time August 08, 2022
arrow
News | Lung Imaging

August 8, 2022 — A clinical trial is only as powerful as its participants. For years, researchers have struggled to fill ...

Time August 08, 2022
arrow
News | Proton Therapy

August 5, 2022 — IBA (Ion Beam Applications S.A., EURONEXT), a world leader in particle accelerator technology, Fred ...

Time August 05, 2022
arrow
News | Radiology Business

August 4, 2022 — The Biden Administration, through the U.S. Department of Health and Human Services and the Centers for ...

Time August 04, 2022
arrow
News | Pediatric Imaging

August 3, 2022 — The Jack Martin Fund (JMF) has built on its partnership with the Mount Sinai Health System to provide ...

Time August 03, 2022
arrow
Feature | Oncology Information Management Systems (OIMS)

August 2, 2022 — The oncology information systems market is projected to be worth $2.59 Bn by 2022 and is expected to ...

Time August 02, 2022
arrow
Feature | Lung Imaging

August 1, 2022 — In recognition of World Lung Cancer Day, the American Lung Association announced new patient resources ...

Time August 01, 2022
arrow
Subscribe Now